Colitis, Ulcerative
Pipeline by Development Stage
Drug Modality Breakdown
On Market (6)
Approved therapies currently available
Competitive Landscape
14 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 30 trials with date data
Clinical Trials (31)
Total enrollment: 8,005 patients across 31 trials
Determination of the Optimal Treatment Target in Ulcerative Colitis
TITRATE (inducTIon for acuTe ulceRATivE Colitis)
An Open Label Phase 4 Study to Evaluate Efficacy of Early Versus Late Use of Vedolizumab in Ulcerative Colitis
Correlation of Soluble Suppression of Tumorigenicity 2 (ST2) With Golimumab (MK-8259) Response in Participants With Ulcerative Colitis (UC) (MK-8529-022).
Phase III Multicentre Trial of Oral Mesalazine in Patients With Mild to Moderate Ulcerative Colitis.
A Study to Evaluate the Safety and Efficacy of AJM300 in Participants With Active Ulcerative Colitis
To Evaluate the Efficacy and Safety of FE 999315 in Japanese Subjects With Mild to Moderate Active Ulcerative Colitis
An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis
(CB-01-02/06) Oral Budesonide-Multi-Matrix System (MMX) 9mg Extended Release Tablets
BI655130 (SPESOLIMAB) Induction Treatment in Patients With Moderate-to-severe Ulcerative Colitis
A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC)
A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE)
BI 655130 Long-term Treatment in Patients With moderate-to Severe Ulcerative Colitis
A Study in Patients With Mild or Moderate Ulcerative Colitis Who Take a TNF Inhibitor. The Study Investigates Whether Bowel Inflammation Improves When Patients Take BI 655130 in Addition to Their Current Therapy
This Study Tests How BI 655130 Works in Patients With Active Ulcerative Colitis. The Study Also Tests How Well BI 655130 is Tolerated and Whether it Helps the Patients
Safety, Efficacy, and Tolerability Study of PF-06480605 in Subjects With Moderate to Severe Ulcerative Colitis.
Trichuris Suis Ova Treatment in Left-sided Ulcerative Colitis
A Study of MK-7240 in Healthy Participants
Pharmacokinetic (PK) Characterization of Subcutaneous Tulisokibart (MK-7240-010)
Single Dose Study of Tulisokibart (MK-7240) in Healthy Chinese Participants (MK-7240-002)
A Phase I Study of LY3471851 in Healthy Participants
A Single-Dose Study of LY3471851 in Healthy Participants
A Study of LY3471851 in Participants With Eczema
A Study of LY3471851 in Healthy Participants
A Study of NKTR-358 (LY3471851) in Healthy Participants
Single Dose Escalation Trial to Evaluate the Safety, Tolerability Pharmacokinetics and Pharmacodynamics of GSK3050002
A Phase 1b Study to Assess the Safety and Anti-inflammatory Effects of Two Different Doses of SRT2104 in Patients With Ulcerative Colitis
Provide Pre-approval Single Patient Expanded Access (Compassionate Use) of Etrasimod for Patients.
JAK Inhibition in Ulcerative Colitis
Sub-optimal Response to Anti-Tumor Necrosis Factor's in Inflammatory Bowel Disease in Emerging Markets
Inflammatory Bowel Disease in South Eastern Norway